Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Filtra i risultati della ricerca
Seleziona modelli di dati

Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

21 Risultati di ricerca.

Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314 - Therapy and toxicity cycle 10-13

- 20/09/21 - 16 moduli, 16 itemgroups, 68 elementi, 1 linguaggio

Itemgroups: Therapy cycle 10-13, Therapy after cycle, Propranolol, Propranolol therapy deviation, Celecoxib, Celecoxib deviation, Cyclophosphamide, Cyclophosphamide deviation, Vinblastine, Vinblastine deviation, Toxicity overview, Toxicity, Hospitalization, Comments, Transfusion, Footer module

NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln

Therapy and toxicity cycle > 13

16 itemgroups 68 elementi

Therapy and toxicity cycle 1-3

16 itemgroups 68 elementi

Therapy and toxicity cycle 4-6

16 itemgroups 68 elementi

Therapy and toxicity cycle 7-9

16 itemgroups 68 elementi

Baseline

13 itemgroups 77 elementi

Reference

12 itemgroups 111 elementi

dbGaP phs000868 Transcriptome Sequencing of Pediatric Neuroblastoma - Eligibility

- 16/03/24 - 5 moduli, 1 ItemGroup, 1 elemento, 1 linguaggio

ItemGroup: IG.elig

Principal Investigator: Javed Khan, National Institutes of Health, Bethesda, MD, USA MeSH: Neuroblastoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000868 Neuroblastoma is the most common extra-cranial solid tumor in children. It represents 8% to 10% of all childhood cancers. Stage 4 Neuroblastoma is characterized by its clinical heterogeneous outcome. The special category, stage 4S tumors (2-5% of all NB) are chemo-sensitive, and the patients show spontaneous regression. On the other hand, MYCN amplification (25-30% of all NB) is associated with poor outcome of neuroblastoma, thus we further categorize stage 4 neuroblastoma into MYCN non-amplified and MYCN amplified group. Here we use transcriptome sequencing to characterize the transcriptome in 29 stage 4 Neuroblastoma samples.

Neuroblastoma

pht004587.v1.p1

1 ItemGroup 2 elementi

pht004588.v1.p1

1 ItemGroup 3 elementi

pht004589.v1.p1

1 ItemGroup 2 elementi

pht004590.v1.p1

1 ItemGroup 7 elementi

dbGaP phs000124 Genome-Wide Association Study of Neuroblastoma - Eligibility

- 12/10/22 - 4 moduli, 1 ItemGroup, 2 elementi, 1 linguaggio

ItemGroup: IG.elig

Principal Investigator: John M. Maris, Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA MeSH: Neuroblastoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000124 Neuroblastoma is a malignancy of the developing sympathetic nervous system that most commonly affects young children and is often lethal. The etiology of this embryonal cancer is not known. We have performed a whole genome scan for association of neuroblastoma with SNP genotypes and copy number variation to discover predisposition loci. We therefore initiated a genome-wide association study (GWAS) in 2007 focused on neuroblastoma patients identified through the Children's Oncology Group (COG; 238 member institutions). Control patients for this study are children cared for at the Children's Hospital of Philadelphia (CHOP) without a diagnosis of cancer. The study was designed to collect up to 5000 neuroblastoma cases and 10,000 controls and is powered to detect common susceptibility variants in Caucasian and African American patients. Whole genome genotyping is being performed on the Illumina HH550 SNP array.

pht002172.v1.p1

1 ItemGroup 2 elementi

pht002173.v1.p1

1 ItemGroup 12 elementi

pht002171.v1.p1

1 ItemGroup 3 elementi

Neuroblastoma (NCT00053326) - End of Course Worksheet (ANBL0321 NCT00053326)

- 19/03/15 - 1 modulo, 4 itemgroups, 46 elementi, 1 linguaggio

Itemgroups: Header, Tumor therapy, Patient status, Adverse event

ANBL0321: End of Course Worksheet Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C42A83E1-AFEA-713E-E034-0003BA12F5E7

Neuroblastoma NCT00053326 Transmittal - Immunocytology Specimen Shipping Form [ANBL0321] - 2174356v3.0 - Immunocytology Specimen Shipping Form [ANBL0321]

- 09/01/15 - 1 modulo, 3 itemgroups, 33 elementi, 1 linguaggio

Itemgroups: Header, Patient Information, CCRR MODULE

Immunocytology Specimen Shipping Form [ANBL0321] Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=C427B2DA-BD65-633A-E034-0003BA12F5E7

Neuroblastoma NCT00053326 Off Treatment - ANBL0321 Off Protocol Therapy Follow-up (OPTF) Report (Master) - 2089607v3.0 - ANBL0321 Off Protocol Therapy Follow-up (OPTF) Report (Master)

- 09/01/15 - 1 modulo, 4 itemgroups, 26 elementi, 1 linguaggio

Itemgroups: Header, Patient Status Information, Events of Interest, CCRR MODULE

ANBL0321 Off Protocol Therapy Follow-up (OPTF) Report (Master) Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B9B484F8-51DB-1EF7-E034-0003BA12F5E7

Neuroblastoma NCT00053326 Pre-Study - ANBL0321: CT/MRI Sites of Disease at study entry - 2089140v3.0 - ANBL0321: CT/MRI Sites of Disease at study entry

- 09/01/15 - 1 modulo, 3 itemgroups, 19 elementi, 1 linguaggio

Itemgroups: Header, Sites of Measurable Disease at the Time of Study Entry, CCRR MODULE

ANBL0321: CT/MRI Sites of Disease at study entry Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B966743D-6A11-0A66-E034-0003BA12F5E7

dbGaP phs000744 Yale Center for Mendelian Genomics (Y CMG) - pht003977.v4.p2

- 11/12/22 - 5 moduli, 1 ItemGroup, 5 elementi, 1 linguaggio

ItemGroup: pht003977

Principal Investigator: Richard Lifton, Yale University, New Haven, CT, USA MeSH: Familial Idiopathic Pulmonary Fibrosis,Aortic Coarctation,Aortic Stenosis, Supravalvular,Aortic Valve, Bicuspid,Arteries,Blepharophimosis,Bronchiectasis,Carcinoma, Renal Cell,Cardiomyopathies,Ciliary Motility Disorders,Cleft Palate,Congenital Abnormalities,Diaphragmatic Hernia,Ductus Arteriosus, Patent,Gastroschisis,Heart Defects, Congenital,Heart Septal Defects, Atrial,Heart Valve Diseases,Hemangioma,Hereditary Sensory and Autonomic Neuropathies,Hydrocephalus,Hyper-IgM Immunodeficiency Syndrome,Hyperaldosteronism,Hypertension,Ichthyosiform Erythroderma, Congenital,Idiopathic Pulmonary Fibrosis,Lung Diseases, Interstitial,Muscular Atrophy, Spinal,Neuroblastoma,Pneumothorax,Pulmonary Atresia,Pulmonary Valve Stenosis,Rett Syndrome,Spina Bifida,Tetralogy of Fallot,Transposition of Great Vessels,Tricuspid Atresia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000744 Yale University is home to one of three national centers created by the NIH to study the genetics of rare inherited diseases. Researchers at Yale, the University of Washington, and a center operated jointly by Baylor and Johns Hopkins University will analyze the genomes of thousands of patients who suffer from more than 6,000 rare Mendelian disorders affecting more than 25 million individuals in US. The Centers for Mendelian Genomics will apply next-generation sequencing and computational approaches to discover the genes and variants that underlie Mendelian disorders. The discovery of new genes that cause Mendelian conditions will expand our understanding about their biology to facilitate their diagnosis, and potentially indicate new treatments. The Centers for Mendelian Genomics will provide free exome sequencing and analysis to collaborating investigators for qualified phenotypes. If you are interested in working with the CMG to discover the genetic basis of a Mendelian condition, please contact Yale Center (shrikant.mane@yale.edu) for further information.

pht003978.v4.p2

1 ItemGroup 3 elementi

pht003979.v4.p2

1 ItemGroup 7 elementi

pht003980.v4.p2

1 ItemGroup 2 elementi

pht003976.v4.p2

1 ItemGroup 2 elementi

dbGaP phs001052 Multi-Dimensional ClinOmics for Precision Therapy - Eligibility

- 09/07/23 - 5 moduli, 1 ItemGroup, 1 elemento, 1 linguaggio

ItemGroup: IG.elig

Principal Investigator: MeSH: Neoplasms,Sarcoma,Sarcoma, Ewing,Rhabdomyosarcoma,Wilms Tumor,Desmoplastic Small Round Cell Tumor,Carcinoma, Transitional Cell,Rhabdoid Tumor,Sarcoma, Synovial,Neuroblastoma,Neuroendocrine tumors https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001052 The Center for Cancer Research (CCR), of the intramural NCI undertook a multidimensional clinical genomics study of children and adolescent young adults with relapsed and refractory cancers who were enrolled on other therapeutic trials to determine the feasibility of a genome guided precision therapy protocol in these patients.

pht005466.v2.p1

1 ItemGroup 2 elementi

pht005467.v2.p1

1 ItemGroup 3 elementi

pht005468.v2.p1

1 ItemGroup 3 elementi

pht005469.v2.p1

1 ItemGroup 6 elementi

ANBL0321 MIBG Response NCT00053326

- 20/09/21 - 1 modulo, 5 itemgroups, 6 elementi, 1 linguaggio

Itemgroups: Header, Period Number, Tumor Response, Comments, CCRR MODULE

ANBL0321 MIBG Response NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B968BED1-43CF-22DE-E034-0003BA12F5E7

ANBL0321: Death Worksheet NCT00053326

- 05/07/15 - 1 modulo, 3 itemgroups, 17 elementi, 1 linguaggio

Itemgroups: Header, Death Assessment, CCRR MODULE

ANBL0321: Death Worksheet NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B9B55D16-FD2B-1EE8-E034-0003BA12F5E7

ANBL0321: Relapse/Progression Worksheet NCT00053326

- 03/07/15 - 1 modulo, 3 itemgroups, 13 elementi, 1 linguaggio

Itemgroups: Header, Relapse/Progression, CCRR MODULE

ANBL0321: Relapse/Progression Worksheet NCT00053326 Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B968B3D2-B7BF-21FC-E034-0003BA12F5E7

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.